Cargando…
N-Terminal Pro-B-Type Natriuretic Peptide in Risk Stratification of Heart Failure Patients With Implantable Cardioverter-Defibrillator
BACKGROUND: The prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in heart failure (HF) is well-established. However, whether it could facilitate the risk stratification of HF patients with implantable cardioverter-defibrillator (ICD) is still unclear. OBJECTIVE: To determine...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921256/ https://www.ncbi.nlm.nih.gov/pubmed/35299981 http://dx.doi.org/10.3389/fcvm.2022.823076 |
_version_ | 1784669297522507776 |
---|---|
author | Deng, Yu Cheng, Si-Jing Hua, Wei Cai, Min-Si Zhang, Ni-Xiao Niu, Hong-Xia Chen, Xu-Hua Gu, Min Cai, Chi Liu, Xi Huang, Hao Zhang, Shu |
author_facet | Deng, Yu Cheng, Si-Jing Hua, Wei Cai, Min-Si Zhang, Ni-Xiao Niu, Hong-Xia Chen, Xu-Hua Gu, Min Cai, Chi Liu, Xi Huang, Hao Zhang, Shu |
author_sort | Deng, Yu |
collection | PubMed |
description | BACKGROUND: The prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in heart failure (HF) is well-established. However, whether it could facilitate the risk stratification of HF patients with implantable cardioverter-defibrillator (ICD) is still unclear. OBJECTIVE: To determine the associations between baseline NT-proBNP and outcomes of all-cause mortality and first appropriate shock due to sustained ventricular tachycardia/ventricular fibrillation (VT/VF) in ICD recipients. METHODS AND RESULTS: N-terminal pro-B-type natriuretic peptide was measured before ICD implant in 500 patients (mean age 60.2 ± 12.0 years; 415 (83.0%) men; 231 (46.2%) Non-ischemic dilated cardiomyopathy (DCM); 136 (27.2%) primary prevention). The median NT-proBNP was 854.3 pg/ml (interquartile range [IQR]: 402.0 to 1,817.8 pg/ml). We categorized NT-proBNP levels into quartiles and used a restricted cubic spline to evaluate its nonlinear association with outcomes. The incidence rates of mortality and first appropriate shock were 5.6 and 9.1%, respectively. After adjusting for confounding factors, multivariable Cox regression showed a rise in NT-proBNP was associated with an increased risk of all-cause mortality. Compared with the lowest quartile, the hazard ratios (HRs) with 95% CI across increasing quartiles were 1.77 (0.71, 4.43), 3.98 (1.71, 9.25), and 5.90 (2.43, 14.30) for NT-proBNP (p for trend < 0.001). A restricted cubic spline demonstrated a similar pattern with an inflection point found at 3,231.4 pg/ml, beyond which the increase in NT-proBNP was not associated with increased mortality (p for nonlinearity < 0.001). Fine-Gray regression was used to evaluate the association between NT-proBNP and first appropriate shock accounting for the competing risk of death. In the unadjusted, partial, and fully adjusted analysis, however, no significant association could be found regardless of NT-proBNP as a categorical variable or log-transformed continuous variable (all p > 0.05). No nonlinearity was found, either (p = 0.666). Interactions between NT-proBNP and predefined factors were not found (all p > 0.1). CONCLUSION: In HF patients with ICD, the rise in NT-proBNP is independently associated with increased mortality until it reaches the inflection point. However, its association with the first appropriate shock was not found. Patients with higher NT-proBNP levels might derive less benefit from ICD implant. |
format | Online Article Text |
id | pubmed-8921256 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89212562022-03-16 N-Terminal Pro-B-Type Natriuretic Peptide in Risk Stratification of Heart Failure Patients With Implantable Cardioverter-Defibrillator Deng, Yu Cheng, Si-Jing Hua, Wei Cai, Min-Si Zhang, Ni-Xiao Niu, Hong-Xia Chen, Xu-Hua Gu, Min Cai, Chi Liu, Xi Huang, Hao Zhang, Shu Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: The prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in heart failure (HF) is well-established. However, whether it could facilitate the risk stratification of HF patients with implantable cardioverter-defibrillator (ICD) is still unclear. OBJECTIVE: To determine the associations between baseline NT-proBNP and outcomes of all-cause mortality and first appropriate shock due to sustained ventricular tachycardia/ventricular fibrillation (VT/VF) in ICD recipients. METHODS AND RESULTS: N-terminal pro-B-type natriuretic peptide was measured before ICD implant in 500 patients (mean age 60.2 ± 12.0 years; 415 (83.0%) men; 231 (46.2%) Non-ischemic dilated cardiomyopathy (DCM); 136 (27.2%) primary prevention). The median NT-proBNP was 854.3 pg/ml (interquartile range [IQR]: 402.0 to 1,817.8 pg/ml). We categorized NT-proBNP levels into quartiles and used a restricted cubic spline to evaluate its nonlinear association with outcomes. The incidence rates of mortality and first appropriate shock were 5.6 and 9.1%, respectively. After adjusting for confounding factors, multivariable Cox regression showed a rise in NT-proBNP was associated with an increased risk of all-cause mortality. Compared with the lowest quartile, the hazard ratios (HRs) with 95% CI across increasing quartiles were 1.77 (0.71, 4.43), 3.98 (1.71, 9.25), and 5.90 (2.43, 14.30) for NT-proBNP (p for trend < 0.001). A restricted cubic spline demonstrated a similar pattern with an inflection point found at 3,231.4 pg/ml, beyond which the increase in NT-proBNP was not associated with increased mortality (p for nonlinearity < 0.001). Fine-Gray regression was used to evaluate the association between NT-proBNP and first appropriate shock accounting for the competing risk of death. In the unadjusted, partial, and fully adjusted analysis, however, no significant association could be found regardless of NT-proBNP as a categorical variable or log-transformed continuous variable (all p > 0.05). No nonlinearity was found, either (p = 0.666). Interactions between NT-proBNP and predefined factors were not found (all p > 0.1). CONCLUSION: In HF patients with ICD, the rise in NT-proBNP is independently associated with increased mortality until it reaches the inflection point. However, its association with the first appropriate shock was not found. Patients with higher NT-proBNP levels might derive less benefit from ICD implant. Frontiers Media S.A. 2022-03-01 /pmc/articles/PMC8921256/ /pubmed/35299981 http://dx.doi.org/10.3389/fcvm.2022.823076 Text en Copyright © 2022 Deng, Cheng, Hua, Cai, Zhang, Niu, Chen, Gu, Cai, Liu, Huang and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Deng, Yu Cheng, Si-Jing Hua, Wei Cai, Min-Si Zhang, Ni-Xiao Niu, Hong-Xia Chen, Xu-Hua Gu, Min Cai, Chi Liu, Xi Huang, Hao Zhang, Shu N-Terminal Pro-B-Type Natriuretic Peptide in Risk Stratification of Heart Failure Patients With Implantable Cardioverter-Defibrillator |
title | N-Terminal Pro-B-Type Natriuretic Peptide in Risk Stratification of Heart Failure Patients With Implantable Cardioverter-Defibrillator |
title_full | N-Terminal Pro-B-Type Natriuretic Peptide in Risk Stratification of Heart Failure Patients With Implantable Cardioverter-Defibrillator |
title_fullStr | N-Terminal Pro-B-Type Natriuretic Peptide in Risk Stratification of Heart Failure Patients With Implantable Cardioverter-Defibrillator |
title_full_unstemmed | N-Terminal Pro-B-Type Natriuretic Peptide in Risk Stratification of Heart Failure Patients With Implantable Cardioverter-Defibrillator |
title_short | N-Terminal Pro-B-Type Natriuretic Peptide in Risk Stratification of Heart Failure Patients With Implantable Cardioverter-Defibrillator |
title_sort | n-terminal pro-b-type natriuretic peptide in risk stratification of heart failure patients with implantable cardioverter-defibrillator |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921256/ https://www.ncbi.nlm.nih.gov/pubmed/35299981 http://dx.doi.org/10.3389/fcvm.2022.823076 |
work_keys_str_mv | AT dengyu nterminalprobtypenatriureticpeptideinriskstratificationofheartfailurepatientswithimplantablecardioverterdefibrillator AT chengsijing nterminalprobtypenatriureticpeptideinriskstratificationofheartfailurepatientswithimplantablecardioverterdefibrillator AT huawei nterminalprobtypenatriureticpeptideinriskstratificationofheartfailurepatientswithimplantablecardioverterdefibrillator AT caiminsi nterminalprobtypenatriureticpeptideinriskstratificationofheartfailurepatientswithimplantablecardioverterdefibrillator AT zhangnixiao nterminalprobtypenatriureticpeptideinriskstratificationofheartfailurepatientswithimplantablecardioverterdefibrillator AT niuhongxia nterminalprobtypenatriureticpeptideinriskstratificationofheartfailurepatientswithimplantablecardioverterdefibrillator AT chenxuhua nterminalprobtypenatriureticpeptideinriskstratificationofheartfailurepatientswithimplantablecardioverterdefibrillator AT gumin nterminalprobtypenatriureticpeptideinriskstratificationofheartfailurepatientswithimplantablecardioverterdefibrillator AT caichi nterminalprobtypenatriureticpeptideinriskstratificationofheartfailurepatientswithimplantablecardioverterdefibrillator AT liuxi nterminalprobtypenatriureticpeptideinriskstratificationofheartfailurepatientswithimplantablecardioverterdefibrillator AT huanghao nterminalprobtypenatriureticpeptideinriskstratificationofheartfailurepatientswithimplantablecardioverterdefibrillator AT zhangshu nterminalprobtypenatriureticpeptideinriskstratificationofheartfailurepatientswithimplantablecardioverterdefibrillator |